This view is supported by in vitro AD models and some clinical data available on NGF treatment in early stages of AD (Enciu et al., 2011; Iulita & Cuello, 2014; Schulte‐Herbruggen et al., 2007). The gene discussed is NGF; the disease is Alzheimer disease.